-------------------------------------------------------------------------------- | NASDAQ OMX Nordic | 22 December 2008 | | | | -------------------------------------------------------------------------------- | Report on transactions of executives and related parties | | | in Coloplast shares and related securities | | -------------------------------------------------------------------------------- According to the Danish Securities Act § 28a Coloplast is obliged to report on the transactions of executives and their related parties in Coloplast shares and related securities. The below transaction deals with allocation of share options: -------------------------------------------------------------------------------- | Name | Lars Rasmussen | -------------------------------------------------------------------------------- | Reason | CEO | -------------------------------------------------------------------------------- | Issuer | Coloplast A/S | -------------------------------------------------------------------------------- | ISIN code | DK0010309657 | -------------------------------------------------------------------------------- | Description | Shares | -------------------------------------------------------------------------------- | Transaction | Share option allocation | -------------------------------------------------------------------------------- | Trade date | 19 December 2008 | -------------------------------------------------------------------------------- | Market | NASDAQ OMX Nordic | -------------------------------------------------------------------------------- | Number | 59,920 | -------------------------------------------------------------------------------- | Value | 38.80 | -------------------------------------------------------------------------------- | Market value in DKK | 2,324,896 | -------------------------------------------------------------------------------- | Own share of expenses | 5% of the Black & Scholes value | -------------------------------------------------------------------------------- -------------------------------------------------------------------------------- | Name | Lene Skole | -------------------------------------------------------------------------------- | Reason | CFO | -------------------------------------------------------------------------------- | Issuer | Coloplast A/S | -------------------------------------------------------------------------------- | ISIN code | DK0010309657 | -------------------------------------------------------------------------------- | Description | Shares | -------------------------------------------------------------------------------- | Transaction | Share option allocation | -------------------------------------------------------------------------------- | Trade date | 19 December 2008 | -------------------------------------------------------------------------------- | Market | NASDAQ OMX Nordic | -------------------------------------------------------------------------------- | Number | 44,460 | -------------------------------------------------------------------------------- | Value | 38.80 | -------------------------------------------------------------------------------- | Market value in DKK | 1,725,048 | -------------------------------------------------------------------------------- | Own share of expenses | 5% of the Black & Scholes value | -------------------------------------------------------------------------------- Calculation of value: When calculating the value of share options the Black & Scholes formula is applied. The formula is described in Coloplast's annual report. The strike price is calculated on basis of the average closing price for all tradings on the date of allocation and the following 4 days plus 15%. Yours sincerely Coloplast A/S Agnete Ingvordsen This information is available in Danish and in English, in case of doubt the Danish version prevails. For further information: Agnete Ingvordsen, tel. +45 49 11 16 12.
Attachments
Recommended Reading
-
Please see enclosed pdf. Update to Financial Calendar Dates Coloplast has updated the dates in its financial calendar for the publication of the FY Financial Statements 2025/26 and the Annual...
Read More -
2025/26Interim financial results, Q1 2025/261 October 2025 - 31 December 2025 Coloplast delivered Q1 organic growth of 6% and EBIT growth1 in constant currencies of 3%. Reported revenue in DKK grew...
Read More